Tivdak® (tisotumab vedotin-tftv) significantly prolonged overall survival in patients with recurrent or metastatic cervical cancer compared with chemotherapy in global phase 3 innovatv 301 trial

Bothell, wash., & copenhagen, denmark--(business wire)--seagen inc. (nasdaq: sgen) and genmab a/s (nasdaq: gmab) announced results today from the phase 3 innovatv 301 randomized global trial, which showed treatment with tivdak demonstrated a statistically significant and clinically meaningful 30% reduction in the risk of death in recurrent or metastatic cervical cancer patients with disease progression on or after first-line therapy, compared with chemotherapy (hr: 0.70, 95% ci: 0.54-0.89, p=0.
SGEN Ratings Summary
SGEN Quant Ranking